Bill
H 1322
Overview: H 1322 is a bill that aims to ensure access to specialty medications. It was introduced on February 27, 2025 and has been accompanied by a new draft, H4497.Purpose and In
Overview: H 1322 is a bill that aims to ensure access to specialty medications. It was introduced on February 27, 2025 and has been accompanied by a new draft, H4497.
Purpose and Intent: The bill's primary goal is to address the challenges faced by patients in accessing specialty medications, which are often high-cost and complex treatments for rare or chronic conditions. The intent is to ensure that patients have reliable and affordable access to these essential medications.
Key Provisions:
- Requires health insurance plans to provide coverage for specialty medications, including those used to treat rare diseases
- Establishes guidelines for the utilization management of specialty medications, such as prior authorization and step therapy requirements
- Prohibits insurers from imposing excessive cost-sharing or other barriers that limit patient access to specialty medications
Affected Parties and Impacts: The bill would primarily impact patients who rely on specialty medications, as well as health insurance providers and pharmaceutical companies. It aims to improve patient outcomes and reduce the financial burden associated with accessing these critical treatments.
Procedural and Timeline Considerations: H 1322 has been accompanied by a new draft, H4497, which suggests that the original bill has been revised or replaced. The current status indicates that the legislative process is ongoing, and the new draft will need to go through the regular committee and voting procedures before it can be enacted.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
